Results 131 to 140 of about 741,060 (264)

EGFR mutation testing trends for patients with metastatic, non-squamous non-small cell lung cancer (non-SQ NSCLC) in Queensland, Australia from 2014-2021

Background: Lung cancer is the leading cause of cancer-related mortality worldwide. Epidermal growth factor receptor (EGFR) is the most common actionable mutation in non-small cell lung cancer (NSCLC) with routine testing recommended globally.
Mason, Robert, Chan, Bryan Anthony, Sanmugarajah, Jasotha, Niranjan, Navin, Yang, Zane, Guan, Tracey   +5 more
core   +1 more source

Staining of resection specimens using EGFR mutation-specific antibodies.

, 2013
The total EGFR protein in resection samples could be stained with EGFR (D38B1) antibody (A, D and G, 200×). Samples without EGFR mutations were not stained with two mutation-specific antibodies (B and C, 200×).
Liang Wang (23021), Xiupeng Zhang (388071), Enhua Wang (93227), Yong Zhang (5893), Shundong Dai (190558), Guiyang Jiang (164288), Yang Liu (4829), Chuifeng Fan (388070), Lianhe Yang (388072), Juanhan Yu (164278), Qianze Dong (164522)   +10 more
core   +1 more source

Supramolecular Degraders: An Emerging Paradigm in Targeted Protein Degradation

Advanced Science, EarlyView.
Dynamic supramolecular assembly reshapes targeted protein degradation by coordinating modular degrader construction, delivery, functional integration, and intracellular assembly or activation across proteasomal, endosomal–lysosomal, and autophagy–lysosomal pathways.
Kongjun Liu, Xue Yuan, Yan Zhou, Rui Yuan, Shaocheng Xie, Yong Chen, Peiyi Wang, Jianmei Gao, Qihai Gong   +8 more
wiley   +1 more source

Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.

, 2011
Epidermal growth factor receptor (EGFR) is a novel target for therapy in subsets of non-small cell lung cancer, especially adenocarcinoma. Tumors with EGFR mutations showed good response to EGFR tyrosine kinase inhibitors (TKIs). We aimed to identify the
Lin Jou-Wei, Meng-Feng Tsai, Wu Chen-Tu, Chang Yih-Leong, Shih Jin-Yuan, Lee Yung-Chie, Yu Chong-Jen, Shang-Gin Wu, Hsuan-Yu Chen, Wu Shang-Gin, Yih-Leong Chang, Jou-Wei Lin, Chong-Jen Yu, Chen-Tu Wu, Jin-Yuan Shih, Chen Hsuan-Yu, Yung-Chie Lee, Tsai Meng-Feng   +17 more
core   +1 more source

The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies

Advanced Science, EarlyView.
This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang, Zhicheng Zhou, Xue Jiang, Zhenguang Du, Yangyang Zhan, Xinli Liu   +5 more
wiley   +1 more source

Proteogenomic characterization of cholangiocarcinoma

Hepatology, EarlyView., 2022
Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng, Peng Ran, Lingli Chen, Yunzhi Wang, Zixiang Yu, Ke Cai, Jinwen Feng, Zhaoyu Qin, Yanan Yin, Subei Tan, Yang Liu, Chen Xu, Guoming Shi, Yuan Ji, Jian‐Yuan Zhao, Jian Zhou, Jia Fan, Yingyong Hou, Chen Ding   +18 more
wiley   +1 more source

AARS1‐Mediated H3K27 Lactylation Rewires Glycolysis to Sustain Aggressive and Recurrent Bladder Cancer

Advanced Science, EarlyView.
AARS1 drives PI3K–AKT–mTOR‐dependent glycolysis in bladder cancer, promoting lactate accumulation, increased lactylation, H3K27la enrichment at the HK2 promoter, and HK2 transcription. HK2 reinforces glycolysis, sustaining a metabolic–epigenetic program associated with tumor progression, recurrence, and metastasis.
Qin Yuan, Tianbao Song, Yipeng He, Sihan Xia, Yaoqiu Huang, Wenlin He, Qin Yi, Zefeng Wang, Peihan Wang, Chenbo Huang, Linzhi Li, Zhen Yin, Fan Cheng, Weimin Yu   +13 more
wiley   +1 more source

14‐3‐3γ Protects Against Postoperative Cognitive Dysfunction by Regulating Tau Thr205 Phosphorylation and Synaptic Integrity

Advanced Science, EarlyView.
Integrative multi‐cohort analyses identify 14‐3‐3γ as a biomarker and regulator of cognitive vulnerability. Experimental studies show that 14‐3‐3γ loss is associated with Tau Thr205 phosphorylation, synaptic dysfunction, and cognitive impairment, while genetic overexpression or pharmacological stabilization of 14‐3‐3γ confers protective effects in ...
Shouqiang Zhu, Xue Han, Heng Zhang, Chang Ye, Tianjiao Xia, Xiaoping Gu   +5 more
wiley   +1 more source

DLST Succinylation‐Mediated Mitochondrial Metabolic Remodeling and Cuproptosis Resistance Promote Malignant Progression of Lung Adenocarcinoma

Advanced Science, EarlyView.
The DLST K409 succinylation mediated by CPT1A promotes OXPHOS and redox homeostasis through regulating enzyme activity, thereby promoting the malignant progression of LUAD. Notably, the succinylation of DLST can enhance the cuproptosis resistance by inhibiting its lipoylation.
Xuanxuan Li, Peijun Zhou, Xingzhi Peng, Qixin Liu, Wenhui Zeng, Rui Wang, Liangfang Shen, Jinwu Peng, Qin Zhou, Lifang Yang   +9 more
wiley   +1 more source

Leveraging Microphysiological Systems to Facilitate Neutrophil‐Based Cancer Immunotherapy

Advanced Science, EarlyView.
Microphysiological systems are emerging as powerful human‐relevant platforms for studying neutrophil biology in cancer. Current applications of spheroids, organoids, and organ‐on‐a‐chip models are reviewed, together with future opportunities in behaviorome profiling, multi‐omics integration, personalized medicine, immune crosstalk, and multi‐organ ...
Shuai Shao, Markus Isfeld Diehl, Caroline N. Jones   +2 more
wiley   +1 more source